IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re t	he Application of:) Group Art Unit: 1648				
	COX) Examiner: Lucas, Zachariah				
Serial 1	No.: 10/773,654)				
Filed: 1	February 5, 2004) SUPPLEMENTAL INFORMATION) DISCLOSURE STATEMENT				
Atty. F	ile No.: 4152-1-PUS-6) <u>DISCLOSURE STATEMENT</u>) Electronically Filed				
For:	"CYSTEINE VARIANTS OF " GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR")				
Comm P.O. B	top Amendment issioner for Patents ox 1450 ndria, VA 22313-1450					
Dear S	ir:					
	The references cited on attached For	m PTO-SB08 are being called to the attention of the				
Exami	ner.					
	□ Copies of the cited non-patent	t and/or foreign references are enclosed herewith.				
	☐ Copies of the cited U.S. patents and/or patent applications are enclosed herewith.					
	☐ Copies of the cited U.S. paten	nts/patent application publications are not enclosed in				
accord	ance with 37 C.F.R. § 1.98(a).					
	□ Copies of the cited reference	es are not enclosed, in accordance with 37 C.F.R.				
§ 1.98(d), because the references were cited by	y or submitted to the U.S. Patent and Trademark Office				
in prio	r application Serial No.	filed, which is relied upon for an				
earlier	filing date under 35 U.S.C. § 120.					
	□ To the best of applicants' belie	ef, the pertinence of the foreign-language references are				
believe	ed to be summarized in the attached En	nglish abstracts and in the figures, although applicants				
do not	o not necessarily vouch for the accuracy of the translation.					

	Examiner's attention	is drawn to the following co-pending applications, copies of
which have	e been or are being submi	tted:
	Serial No.	filed
	Serial No.	filed
	Other:	

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

	37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfies one of the following conditions ("X" indicates satisfaction):			
	Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or			
	Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or			
	Before the mailing date of a first Office Action on the merits, or			
	Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.			
⊠	37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by:			
	A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR			
	Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.			

	37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).
	☐ This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND
	Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.
	Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)
	The undersigned certifies that:
	Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).
	☐ A copy of the communication from the foreign patent office is enclosed.
	OR
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).
	Respectfully submitted,
	SHERIDAN ROSS P.C.
Date: 3	By: Mallas Sebor Registration No. 42,460 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141 (303) 863-9700

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/773,654 **INFORMATION DISCLOSURE** Filing Date February 5, 2004 **STATEMENT BY APPLICANT** First Named Inventor Cox, George N. III Art Unit 1648 **Examiner Name** Lucas, Zachariah Sheet of Attorney Docket Number 4152-1-PUS-6 1

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1.	US-5,229,496	07-20-1993	Deeley et al.		
	2.	US-5,391,485	02-21-1995	Deeley et al.		
	3.	US-5,393,870	02-28-1995	Deeley et al.		
	4.	US-5,602,007	02-11-1997	Dunn et al.		
	5.	US-5,720,952	02-24-1998	Clark et al.		
	6,	US-5,891,429	04-06-1999	Clark et al.		
	7.	US-5,895,646	04-20-1999	Wang		
	8.	US-5,908,763	06-01-1999	Clark et al.		
	9.	US-5,942,221	08-24-1999	Clark et al.		
		US-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Country (ign Patent Document Number': Kind Code ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T _e
		PCT	_					1

	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)					
Examiner Initials*	Cite No.1					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.